Abbott Labs Upgraded by Rothschild Redburn for Device Strength
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowRothschild Redburn has upgraded Abbott Laboratories' (ABT) stock rating, citing strong performance in its medical device segment. This upgrade reflects confidence in the company's growth potential amid a competitive landscape. The specific rating levels and projections were not disclosed in the article. Such upgrades can positively influence investor sentiment and stock price movement for Abbott Labs, positioning it favorably in a challenging market.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- AirBaltic (ABT) Files for Chapter 11 Bankruptcy in New York
- Abbott Laboratories (ABT) Target Raised to $143 with 35% Upside
- Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
- Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
- Adeptus Biotechnologies Stock Rating Maintained by BTIG
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
